Abivax (AAVXF) Gains from Investment Securities (2024 - 2025)
Abivax (AAVXF) posted Gains from Investment Securities of $1.1 million for Q1 2025, down 41.76% on a QoQ basis from $2.0 million in Q2 2024, and up 372.58% year-over-year from $240614.5 in Q1 2024.
Powered by 
Analysis
Abivax (AAVXF) Gains from Investment Securities (2024 - 2025) Analysis & Trends
Abivax has reported Gains from Investment Securities for 2 years, with the latest figure at $1.1 million in Q1 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 211.05 Bn | 197.06 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 181.07 Bn | 177.90 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 132.15 Bn | 124.30 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 82.66 Bn | 74.67 Bn | 3.93 Bn |
| 5 | Argenx Se | 61.74 Bn | 56.55 Bn | 1.37 Bn |
| 6 | Moderna | 54.51 Bn | 49.37 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.05 Bn | 30.74 Bn | 992.69 Mn |
| 8 | Biogen | 31.25 Bn | 29.97 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 29.88 Bn | 29.88 Bn | 1.16 Mn |
| 10 | Abivax | 10.92 Bn | 10.92 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2025 | 1.14 Mn |
| Jun 30, 2024 | 1.95 Mn |
| Mar 31, 2024 | -417,162.92 |